Updated on 15 August 2012
Mumbai: Recognizing India as a model for the global vaccine market, the Biotechnology Industry Organization (BIO) has planned a ‘Fireside Chat: Vaccine Development in India' at the 3rd Annual BIO India International Conference. The conference will be held on September 12-13 at the Grand Hyatt in Mumbai, India. BIO has partnered with the Association of Biotechnology Led Enterprises (ABLE), which represents Indian and Asian biotechnology and pharmaceutical companies, as well as leading investment banks and venture capital firms.
"BIO India will highlight the growth of India vaccine makers and their ability to make high-quality vaccines available at affordable prices, and present opportunities for western companies seeking to do business within India's borders," said Mr Alan Eisenberg, executive vice president of emerging companies and business development at BIO.
Dr Cyrus Poonawalla, founder, chairman and managing director, Serum Institute of India, will discuss vaccine development in India during the Fireside Chat on September 12. Ms Naazneen Karmali, India Editor, Forbes Asia, Mumbai Bureau Manager, Forbes, will lead the discussion with Dr Poonawalla.
Among others, there is a session at BIO India on ‘Commercializing Stem Cell Therapies and Regenerative Medicine'. This session will discuss India's progress in stem cells and gene therapies, and the increasing use of these technologies to treat a host of diseases. Another session will be on ‘Strategies for Success: India's Global Role in Innovation'.